Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Randomized, Controlled, Open-label Trial of Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable Hepatocellular Carcinoma (HCC)

NCT06726161 is registered in ClinicalTrials.gov with RayzeBio, Inc. as lead sponsor.

NCT NCT06726161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06726161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Randomized, Controlled, Open-label Trial of Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable Hepatocellular Carcinoma (HCC)
Lead sponsor
RayzeBio, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 5, 2025
Completion date
June 30, 2031
Enrollment
590 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)